ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SCLXW Scilex Holding Company

0.21
-0.0009 (-0.43%)
Oct 11 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 435
Bid Price 0.118
Ask Price 0.3996
News -
Company Name Stock Ticker Symbol Market Type
Scilex Holding Company SCLXW NASDAQ Equity Warrant
  Price Change Change Percent Stock Price Last Traded
-0.0009 -0.43% 0.21 16:02:30
Open Price Low Price High Price Close Price Prev Close
0.244 0.21 0.244 0.21 0.2109
Trades Volume VWAP Dollar Volume Avg Volume
6 435  0.2099999  91 -
Last Trade Time Type Quantity Stock Price Currency
16:00:00 425  0.21 USD

Scilex Holding Company Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
32.89M 155.94M - 46.74M -114.33M -0.73 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News Scilex

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No SCLXW Message Board. Create One! See More Posts on SCLXW Message Board See More Message Board Posts

SCLXW Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. ZTlido (lidocaine topical system) 1.8% is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of neuropathic pain associated with post-herpetic neuralgia. We have acquired two FDA approved non-opioid pain products, GLOPERBA and ELYXYB, for the treatment of gout in adults and oral solution for the acute treatment of migraine, with or without aura, in adults. Our product candidates include SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA TM), a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, SP-103 (lidocaine topical system) 5.